Peptide Research Hub
Educational reference
Educational reference only. Nothing on this site is medical advice. Many compounds described here are not FDA-approved, lack adequate human evidence, and may be illegal in your jurisdiction. Always consult a licensed clinician.

Longevity & Anti-Aging

Epithalon

Alanyl-Glutamyl-Aspartyl-Glycine (AEDG tetrapeptide)

Also known as: Epitalon AEDG

Evidence: Preclinical only Disclaimer: Critical Not FDA-approved

Mechanism & research context

Synthetic tetrapeptide studied by the Khavinson research group for putative telomerase activation and pineal-modulating effects. Independent replication is limited.

Safety flags

0 flags

No curator-recorded safety flags for this entry. Absence of recorded flags is not evidence of safety. Many peptides lack adequate human data.

Research papers

17 records

Citation links route to PubMed, Europe PMC, and PMC. Presence of a study is not endorsement. Records are refreshed from PubMed on a regular cadence; rows marked “Live search link” will resolve to a current PubMed search until a full citation has been ingested.

  • · 2026 Open access

    Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

  • · 2026 Open access

    Efficacy and Safety of Melatonin in Migraine Prophylaxis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

  • · 2026 Open access

    Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.

  • · 2025 Open access

    Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties.

  • · 2025 Open access

    Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity.

  • · 2024 Open access

    Biomedicines in Longevity and Aging the Quest to Resist Biological Decline.

  • · 2024

    [Peptidergic regulation of expression of cellular aging marker proteins in buccal epithelium.]

  • · 2015

    Effects of Geroprotectors on Age-Related Changes in Proteolytic Digestive Enzyme Activities at Different Lighting Conditions.

  • · 2013

    [Genome instability in pulmonary tuberculosis before and after treatment].

  • · 2013

    [Functional regulation of genome with peptide bioregulators by hypertrophic cardiomyopathy (by patients and relatives)].

  • · 2013

    [Protective effect of melatonin and epithalon on hypothalamic regulation of reproduction in female rats in its premature aging model and on estrous cycles in senescent animals in various lighting regimes].

  • · 2012

    [Morphofunctional and molecular bases of pineal gland aging].

  • · 2011

    Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA.

  • · 2008

    [Effects of epithalon and cortagene on immunity and hemostasis in neonatally hypophysectomized chicken and old birds].

  • · 2008

    [The influence of melatonin and epithalon on blood leukocyte count and leukocyte alkaline phosphatase in rats under different lighting conditions during ontogenesis].

  • Review · PubMed (NCBI) Live search link

    PubMed literature search: Epithalon

    Run importer to populate live PubMed records. This placeholder links to a live search.

  • Review · Open-access overview (PMC) Open access

    Epitalon Overview (PMC11943447)

    Overview of Epitalon preclinical data and limited human studies from the Khavinson research group.

Clinical trials

1 record

Doses reported in studies

0 records
This is not a dosing guide. Entries below are historical metadata transcribed verbatim from a cited clinical-trial protocol, published study, or FDA-approved label. They describe what was administered in a specific study population under medical supervision — they are not recommendations, not common-use guidance, and may not be safe or appropriate outside the cited context. Doses widely discussed in community/anecdotal sources are not shown here; see the safety policy for why.

No study-protocol dose records have been curated for Epithalon yet. Absence of records is not evidence of safety — many peptides lack adequate human-trial data in the first place.

Records here are populated from public sources only (ClinicalTrials.gov protocol summaries and FDA-approved labels) and must cite a verifiable source URL. They are not added from forum posts, vendor pages, anecdotal write-ups, or social media.

These entries describe what was studied. They do not tell you what to take, how to reconstitute anything, how to fill a capsule, how often to administer, or where to obtain a compound. If you are considering use of Epithalon, those decisions belong with a licensed clinician working from the full label or trial record — not from this summary.

Why this page does not list a dose for self-use

The "Doses reported in studies" section above (when populated) describes what was administered in a cited study or label, under medical supervision, in a specific population. It is not a dosing guide for self-use. Separately, we do not publish anecdotal or community-reported dose ranges, administration methods, vial concentrations, or capsule masses for Epithalon. Anecdotal figures for unapproved compounds are not harm-reduction data: they lack denominators for adverse events, cannot account for individual physiology or compound purity, and normalise unsupervised use. See the safety policy for the full reasoning.

If this compound has an FDA-approved label

If a label exists, the regulator-reviewed dosing and administration information is there — read it in the context of a prescriber's evaluation.

Questions worth bringing to a clinician

  • What is the evidence for this compound in someone with my history?
  • What are the realistic, regulator-reviewed alternatives?
  • What would you monitor, and what would make you stop?

If you have already taken a peptide and feel unwell: contact emergency services. In the United States, Poison Control is reachable 24/7 at 1-800-222-1222. Do not wait for a community thread.

Research peptides are not substitutes for medical care. If you are considering any peptide for health purposes, speak with a board-certified physician or endocrinologist first.